Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | 1780876 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
patient had not reported any adverse issues or side effects related to the administered dose; GARDASIL 9 (lot: 1780876 expiration: 11/09/2023) on 11/28/2022 needed to have the series restarted when she came into the clinic today; This spontaneous report was received from a physician and refers to a 26-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 28-Nov-2022, the patient was vaccinated with first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) 0.5 mL, once strength, frequency, route of administration, site of administration, and vaccination scheme were not provided; lot # 1780876which has been verified as a valid number, and expiration date reported and validated as 09-Nov-2023) as a prophylaxis. On 04-Mar-2025, the patient was vaccinated with second dose (series restarted) with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, frequency, route of administration, site of administration, vaccination scheme, expiration date, and lot # were not reported) as a prophylaxis (Inappropriate schedule of product administration). The patient had not reported any adverse issues or side effects related to the administered dose. For the second dose lot # is being requested and will be submitted in received.